Sagimet Biosciences (SGMT) Competitors $4.94 -0.03 (-0.60%) (As of 12/24/2024 04:10 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SGMT vs. ORIC, AUTL, HUMA, VECT, ANNX, ALT, DNA, TRML, ATXS, and MREOShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include ORIC Pharmaceuticals (ORIC), Autolus Therapeutics (AUTL), Humacyte (HUMA), VectivBio (VECT), Annexon (ANNX), Altimmune (ALT), Ginkgo Bioworks (DNA), Tourmaline Bio (TRML), Astria Therapeutics (ATXS), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. ORIC Pharmaceuticals Autolus Therapeutics Humacyte VectivBio Annexon Altimmune Ginkgo Bioworks Tourmaline Bio Astria Therapeutics Mereo BioPharma Group Sagimet Biosciences (NASDAQ:SGMT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Does the MarketBeat Community prefer SGMT or ORIC? ORIC Pharmaceuticals received 36 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.30% of users gave Sagimet Biosciences an outperform vote while only 72.09% of users gave ORIC Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2696.30% Underperform Votes13.70%ORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% Which has higher valuation and earnings, SGMT or ORIC? Sagimet Biosciences has higher revenue and earnings than ORIC Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M75.77-$27.88MN/AN/AORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-4.55 Is SGMT or ORIC more profitable? Sagimet Biosciences' return on equity of -23.63% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% ORIC Pharmaceuticals N/A -42.47%-38.86% Which has more volatility and risk, SGMT or ORIC? Sagimet Biosciences has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Does the media refer more to SGMT or ORIC? In the previous week, ORIC Pharmaceuticals had 5 more articles in the media than Sagimet Biosciences. MarketBeat recorded 5 mentions for ORIC Pharmaceuticals and 0 mentions for Sagimet Biosciences. ORIC Pharmaceuticals' average media sentiment score of 0.66 beat Sagimet Biosciences' score of 0.00 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Sagimet Biosciences Neutral ORIC Pharmaceuticals Positive Do analysts prefer SGMT or ORIC? Sagimet Biosciences presently has a consensus price target of $23.00, indicating a potential upside of 365.59%. ORIC Pharmaceuticals has a consensus price target of $18.29, indicating a potential upside of 123.27%. Given Sagimet Biosciences' higher probable upside, equities research analysts clearly believe Sagimet Biosciences is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in SGMT or ORIC? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 17.6% of Sagimet Biosciences shares are held by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummarySagimet Biosciences beats ORIC Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad StocksToTradeliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the liberals broke”... But it turns out that was all just a smokescreen to hide the TRUTH…Click here to discover the real reason Elon Musk became buddy-buddy with Trump. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$151.53M$6.70B$5.24B$9.28BDividend YieldN/A2.98%5.12%4.28%P/E RatioN/A10.4287.3817.26Price / Sales75.77206.681,164.33121.12Price / CashN/A57.1543.3837.82Price / Book1.245.174.844.94Net Income-$27.88M$151.96M$121.05M$225.76M7 Day Performance-2.56%3.11%2.49%3.92%1 Month Performance-4.45%-4.17%17.57%1.71%1 Year Performance-15.99%7.50%28.57%15.79% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences2.372 of 5 stars$4.94-0.6%$23.00+365.6%-10.5%$151.53M$2M0.008Gap UpORICORIC Pharmaceuticals3.9157 of 5 stars$8.34+1.6%$18.29+119.3%-7.8%$588.53MN/A-4.6380Positive NewsGap DownAUTLAutolus Therapeutics2.8623 of 5 stars$2.20-3.9%$10.40+372.7%-60.4%$585.41M$10.09M-1.82330Gap DownHUMAHumacyte3.4075 of 5 stars$4.63-0.2%$13.71+196.2%+56.6%$582.73M$1.57M-3.46150Analyst ForecastHigh Trading VolumeVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030ANNXAnnexon2.0006 of 5 stars$5.23flat$15.80+202.1%+30.4%$557.49MN/A-4.9860ALTAltimmune1.8666 of 5 stars$7.79-5.6%$20.00+156.7%-18.6%$554.06M$52,000.00-5.0350Positive NewsDNAGinkgo Bioworks0.6616 of 5 stars$9.37-7.0%$4.58-51.2%N/A$538.58M$217.11M-0.721,218TRMLTourmaline Bio2.6251 of 5 stars$20.87+1.1%$54.00+158.7%-9.3%$535.17MN/A-7.4044Positive NewsATXSAstria Therapeutics2.0558 of 5 stars$9.47-0.9%$25.60+170.3%+40.5%$534.43MN/A-4.5330Positive NewsMREOMereo BioPharma Group2.214 of 5 stars$3.33-0.6%$7.40+122.2%+78.9%$516.64M$1M0.0040Analyst UpgradeNews CoverageGap Up Related Companies and Tools Related Companies ORIC Pharmaceuticals Competitors Autolus Therapeutics Competitors Humacyte Competitors VectivBio Competitors Annexon Competitors Altimmune Competitors Ginkgo Bioworks Competitors Tourmaline Bio Competitors Astria Therapeutics Competitors Mereo BioPharma Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SGMT) was last updated on 12/26/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk could help pay for your retirementElon Musk is the richest man in the world... And he's pouring trillions into a unique investment.Brownstone Research | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
